Nature Study Identifies Ral-CTSA Pathway That Degrades LDLR, Pointing to 100 mg/kg Cholesterol Therapy
Updated
Updated · Nature.com · Jun 24
Nature Study Identifies Ral-CTSA Pathway That Degrades LDLR, Pointing to 100 mg/kg Cholesterol Therapy
3 articles · Updated · Nature.com · Jun 24
Summary
Researchers found that chronic dietary cholesterol activates RAS and Ral in the liver, pushing LDL receptors into lysosomes for degradation and reducing cholesterol clearance independently of PCSK9 or transcriptional control.
The pathway works through the RalBP1-REPS1 endocytic complex and cathepsin A, or CTSA, which matures in lysosomes and accelerates LDLR breakdown while suppressing receptor recycling back to the cell surface.
Mouse and hepatocyte experiments showed that activating Ral lowered hepatic LDLR and worsened cholesterol handling, while genetic variants in the same pathway were significantly linked to altered cholesterol levels in humans.
Pharmacological blockade strengthened LDLR function: the Ral inhibitor RBC8 at 50 mg/kg and a CTSA inhibitor at 100 mg/kg improved cholesterol clearance in preclinical models, highlighting a potential new treatment route for hypercholesterolaemia and cardiovascular disease.
Could a promising new cholesterol drug, repurposed from human trials, inadvertently trigger a severe genetic disease?
Scientists just found the liver's cholesterol self-destruct switch. Can they now safely turn it off?
Breakthrough in LDL Cholesterol Management: Ral-CTSA Pathway and SAR164653 Inhibitor Offer Hope for Statin-Intolerant Patients
Overview
A major breakthrough published in June 2026 revealed a new biological pathway, called the Ral-CTSA pathway, that explains how high dietary cholesterol leads to increased levels of bad LDL cholesterol. The process starts when excess cholesterol in the diet activates the Ral protein in liver cells, which then triggers the enzyme cathepsin A (CTSA). This activation causes the breakdown of LDL receptors on liver cells, reducing the liver’s ability to clear LDL cholesterol from the blood. This discovery opens the door to new treatments that target this pathway, offering hope for better cholesterol management.